Long-acting HIV fusion inhibitor and application thereof

Abstract

The invention belongs to the field of biological medicine, and relates to a long-acting HIV fusion inhibitor for treating acquired immune deficiency syndrome and application thereof. The long-acting HIV fusion inhibitor comprises a polypeptide part for inhibiting HIV membrane fusion and a part capable of being specifically combined with human immune globulin Fc, it is proved through experiments that the half-life period of the long-acting HIV fusion inhibitor in a rhesus monkey is about 11 times that of the HIV fusion inhibitor T20 which is first approved for marketing and has excellent antiviral activity to HIV-1IIIB and HIV-1Bal, the IC50 values are about 5.9 nM and 2.57 nM respectively, the antiviral activity is about 3 times that of T20, and the long-acting HIV fusion inhibitor has low toxicity to cells. The long-acting HIV fusion inhibitor IBP-CP24 polypeptide can be used for preparing a drug for resisting human immunodeficiency viruses for a long time and providing a new strategy for prolonging the half-life period of protein and polypeptide drugs in the body.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

AI Technical Summary

Benefits of technology

This patented technology describes an improved method called Long Acting Anti-Human Immunodeficiency Viruses (LACV) immune therapy with specific short sequences from certain proteins or other substances found naturally occurring within infected individuals' bodies. These LACVs are designed to prevent virus transmission between humans through their ability to attach themselves to cells without causing harmful side reactions like those caused when they were previously exposed during previous exposures. They also have very little potential negative impact on human health compared to older agents such as lymphocyte growth factor.

Problems solved by technology

The technical problem addressed in this patented text relates to developing a long acting antireflective agent called IAVI®(Immediate Release Humant Defense Antiexia Agents or Antiarrhythm Drugs) targeting at least one specific area where patients may contract severe illnesses like Acute Hemorrhagism/Earvidemias. Current methods require frequent injection over multiple months, leading to increased costs associated with patient compliance. Additionally, existing approaches often result in reduced efficacy because they only work within narrow ranges of concentrations.

Images